telcagepant

structure in first source

Also Known As:

MK 0974; MK-0974; MK0974; N-((3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)hexahydro-1h-azepin-3- yl)-4-(2-oxo-2,3-dihydro-1H-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxamide; N-(6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxamide

Networked: 69 relevant articles (17 outcomes, 23 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - telcagepant: 69
  - Azepines: 11
    - telcagepant: 69

Experts

1.	Ho, Tony W: 12 articles (02/2016 - 12/2008)
2.	Lines, Christopher: 10 articles (02/2016 - 12/2008)
3.	Edvinsson, Lars: 6 articles (09/2014 - 02/2008)
4.	Tfelt-Hansen, Peer: 6 articles (06/2011 - 03/2009)
5.	Goadsby, Peter J: 4 articles (01/2020 - 02/2012)
6.	Kost, James: 4 articles (02/2012 - 12/2008)
7.	Murphy, M Gail: 4 articles (06/2011 - 01/2010)
8.	Paone, Daniel V: 4 articles (12/2009 - 02/2008)
9.	Ashina, Messoud: 3 articles (01/2020 - 12/2010)
10.	Assaid, Christopher: 3 articles (02/2016 - 12/2008)

Related Diseases

1.	Migraine Disorders (Migraine) 11/01/2007 - "The proven efficacy of this agent, and also the CGRP antagonist MK-0974, to alleviate acute migraine headache provided significant support for the hypothesis that CGRP has an important role in migraine pathophysiology. " 12/01/2010 - "Telcagepant 140 mg and 280 mg were effective for treatment of a migraine attack and were more consistently effective than control for intermittent treatment of up to four migraine attacks. " 05/15/2009 - "Results from phases II and III clinical trials have suggested that telcagepant is effective for migraine treatment. " 02/01/2015 - "These findings indicate that telcagepant can be effective for treating acute migraine. " 01/01/2011 - "Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial."
2.	Headache (Headaches) 04/05/2013 - "Moreover, the remission rate of unrelenting headache was higher after 24 hours of 300 mg/d telcagepant treatment compared with 150 mg/d (OR = 0.78, 95% CI: 0.62-0.97, P < 0.05). " 12/01/2009 - "For the orally bioavailable CGRP antagonist telcagepant 300 mg, the headache relief was only 55% in one phase III study. " 02/01/2016 - "Telcagepant did not reduce monthly headache frequency, but did reduce perimenstrual headaches." 02/01/2016 - "However, telcagepant was associated with a reduction in on-drug headache days (treatment difference -0.4 day (95% CI: -0.5, -0.2), nominal p < 0.001). " 02/01/2016 - "In the efficacy subset there was no significant effect of telcagepant (n = 887) vs placebo (n = 447) in mean monthly headache days (treatment difference -0.5 day (95% CI: -1.1, 0.1)). "
3.	Coronary Artery Disease (Coronary Atherosclerosis) 06/01/2011 - "Results of this study support further evaluation of telcagepant in patients with stable coronary artery disease." 06/01/2011 - "The primary purpose of the study was to explore the safety and tolerability of telcagepant in patients with stable coronary artery disease. " 06/01/2011 - "In this randomized, double-blind, placebo-controlled, crossover study, patients with documented stable coronary artery disease were assigned to 1 of 2 treatment sequences: telcagepant then placebo, or placebo then telcagepant. " 02/01/2012 - "To evaluate the efficacy of telcagepant in patients with migraine and coronary artery disease. " 02/01/2012 - "The study was underpowered due to enrollment difficulties and did not demonstrate a significant efficacy difference between telcagepant and placebo for the treatment of a migraine attack in patients with stable coronary artery disease. "
4.	Pain (Aches) 02/01/2015 - "The difference in pain relief at 2 hours significantly favored telcagepant over placebo (odds ratio = 2.48, 95% confidence interval = 2.18-2.81, P < 0.001). " 02/01/2012 - "Telcagepant was not statistically different from placebo for 2-hour pain freedom (25.0% vs 18.9%, odds ratio = 1.62 [95% confidence interval: 0.62, 4.25]). " 02/01/2012 - "The primary efficacy analysis evaluated telcagepant vs placebo on 2-hour pain freedom during the first attack of Period 1. One hundred and sixty-five of the planned 400 patients were enrolled, and 114 took at least one dose of treatment. " 01/01/2011 - "The 2-hour pain relief rates were similar across HTR subgroups for telcagepant 150 mg (48-58%), 300 mg (52-58%), and placebo (26-31%). " 12/01/2010 - "The percentage of patients with 2-hour pain freedom consistency and 2-hour pain relief consistency was significantly (p < .001) higher for both telcagepant treatment sequences versus control. "
5.	Epilepsy (Aura) 09/22/2009 - "Adults with migraine with or without aura (International Headache Society criteria) treated a moderate or severe attack with oral telcagepant 50 mg (n = 177), 150 mg (n = 381), 300 mg (n = 371), or placebo (n = 365) in a randomized, double-blind trial. " 04/05/2013 - "The included studies were double-blind, randomized and placebo-controlled trials of olcegepant or telcagepant for the treatment of single acute migraine in patients with or without aura. " 12/01/2010 - "Telcagepant is a novel, orally active, and selective calcitonin gene-related peptide receptor antagonist being developed for acute treatment of migraine with and without aura. "

Related Drugs and Biologics

1.	Calcitonin Gene-Related Peptide Receptor Antagonists
2.	olcegepant
3.	telcagepant
4.	Calcitonin Gene-Related Peptide
5.	Peptides (Polypeptides)
6.	Tryptamines (Triptans)
7.	2- (8- (3,5- difluorophenyl)- 10- oxo- 6,9- diazaspiro(4.5)dec- 9- yl)- N- (2'- oxo- 1,1',2',3- tetrahydrospiro(indene- 2,3'- pyrrolo(2,3- b)pyridin)- 5- yl)acetamide
8.	1- (N(2)- (3,4- dibromo- N- ((4- (3,4- dihydro- 2(1H)- oxoquinazolin- 3- yl)- 1- piperidinyl)carbonyl)tyrosyl)lysyl)- 4- (4- pyridinyl)piperazine
9.	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)
10.	zolmitriptan (Zomig)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug-Eluting Stents
3.	Stents
4.	Aftercare (After-Treatment)